FGFR2 signaling is known to antagonize estrogen signaling pathways, potentially increasing the risk of ER+ BC through its influence on estrogen response.[51] Additionally, the role of FGFR2 varies throughout the stages of mammary gland development, and there is ongoing debate regarding the impact of genetic risk variants on FGFR expression.[21,52]. The gene discussed is FGFR2; the disease is breast cancer.